Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07769346

The Appendix Cancer PMP Research Foundation Natural History Study/Patient Registry

ACPMP's first-ever patient-powered global patient registry/natural history study collects patient and caregiver information and data to fuel clinical trials and drive breakthroughs for appendix cancer and PMP. We've invested the time and resources to make our Registry regulatory grade. Our Registry operates under active, ongoing Institutional Review Board (IRB) oversight by independent ethicists. It is powered by NORD's IAMRARE®, an industry gold standard platform built to be consistent with FDA's best thinking on natural history studies.

Recruiting

Interested in participating?

Request Info

Key information

About this study

The ACPMP Research Foundation Appendix Cancer/PMP Patient Registry is a global, patient-powered natural history study designed to systematically collect longitudinal information from individuals affected by appendix cancer and Pseudomyxoma Peritonei (PMP).

The primary aim of the Registry is to improve understanding of these rare diseases, including their characteristics, clinical course, treatment patterns, and progression over time. Information collected through the Registry will help characterize the population affected by appendix cancer and PMP, support the development of recommendations and standards of care, and provide a resource for researchers studying disease biology, treatment outcomes, and accelerate the discovery of new treatments.

Participants, caregivers, and other authorized representatives provide information through a series of online surveys that include a prompt for patients to upload pathology reports, genomic sequencing, ctDNA reports and other relevant medical documents. Retrospective and prospective data collected include sociodemographic information, medical and diagnostic history, treatments, disease progression, management of care, and quality of life. Participants are asked to return periodically to update their information, allowing changes in disease and patient experience to be evaluated over time.

The Registry also serves as a resource to support future research and clinical trial development. With appropriate review and approval, Registry data may be used by researchers conducting retrospective studies or designing prospective studies of novel treatments. The Registry may also facilitate communication with participants about research opportunities and clinical trials for which they may be eligible.

The Registry is sponsored and managed by the Appendix Cancer Pseudomyxoma Peritonei (ACPMP) Research Foundation and is hosted on the National Organization for Rare Disorders (NORD) IAMRARE® platform. The study is conducted under Institutional Review Board (IRB) oversight and follows established procedures for the collection, management, protection, and appropriate research use of participant data.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of appendix cancer.
  • Meets the study inclusion criteria for participation.
  • Participant or, when applicable, a legally authorized representative (LAR) is able to provide informed consent and enter information into the Registry.
  • A designated representative may provide retrospective information for an individual who died from appendix cancer, as permitted by the study protocol.

Exclusion criteria

  • Individuals who do not meet the study inclusion criteria.
  • Individuals for whom required informed consent cannot be obtained.

Treatment and study plan

Primary outcomes

  1. Natural history and clinical course of appendix cancer and Pseudomyxoma Peritonei (PMP)

    Time frame: Up to 5 years

    Characterization of the natural history and clinical course of appendix cancer and Pseudomyxoma Peritonei (PMP) using participant- and caregiver-reported data collected through the ACPMP Patient Registry.

Secondary outcomes

  1. Disease Characteristics

    Time frame: Up to 5 years

    Disease characteristics of appendix cancer and pseudomyxoma peritonei (PMP), including disease type, extent, and other participant-reported disease characteristics.

  2. Treatment History

    Time frame: Up to 5 years

    Cancer treatment history, including surgical procedures, chemotherapy, and other treatments received for appendix cancer and PMP.

  3. Diagnosis

    Time frame: Up to 5 years

    Characteristics and timing of diagnosis of appendix cancer and PMP, including initial diagnosis and diagnostic findings.

  4. Disease Progression

    Time frame: Up to 5 years

    Disease progression over time, based on participant- and caregiver-reported information regarding changes in disease status.

  5. Management of Care

    Time frame: Up to 5 years

    Changes in management of care for appendix cancer and PMP, including treatments, procedures, and changes in care over time.

  6. Signs and Symptoms

    Time frame: Up to 5 years

    Changes in signs and symptoms associated with appendix cancer and PMP over time, based on participant- and caregiver-reported data.

Study contacts

Contact information is provided by the study sponsor or research team.

Margaret Najarian

CONTACT

[email protected]

(833) 227-6773 ext. 704

Sponsors and collaborators

Lead sponsor

Appendix Cancer Pseudomyxoma Peritonei Research Foundation

Other

Collaborators

  • National Organization for Rare Disorders

Registry information

Official study title

The ACPMP Research Foundation Appendix Cancer/PMP Patient Registry

Important dates

Study start
2026
Primary completion
2030
Study completion
2030
First posted
Aug 17, 2026
Registry last updated
Aug 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.